Last reviewed · How we verify
Lanreotide Autogel and Octreotide LAR
Lanreotide Autogel and Octreotide LAR is a Small molecule drug developed by Odense University Hospital. It is currently FDA-approved.
At a glance
| Generic name | Lanreotide Autogel and Octreotide LAR |
|---|---|
| Sponsor | Odense University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (PHASE1)
- Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (PHASE3)
- Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome (PHASE3)
- Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly (PHASE3)
- Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR (PHASE4)
- Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (PHASE1, PHASE2)
- Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (PHASE3)
- Pasireotide LAR and Pegvisomant Study in Acromegaly (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lanreotide Autogel and Octreotide LAR CI brief — competitive landscape report
- Lanreotide Autogel and Octreotide LAR updates RSS · CI watch RSS
- Odense University Hospital portfolio CI
Frequently asked questions about Lanreotide Autogel and Octreotide LAR
What is Lanreotide Autogel and Octreotide LAR?
Lanreotide Autogel and Octreotide LAR is a Small molecule drug developed by Odense University Hospital.
Who makes Lanreotide Autogel and Octreotide LAR?
Lanreotide Autogel and Octreotide LAR is developed and marketed by Odense University Hospital (see full Odense University Hospital pipeline at /company/odense-university-hospital).
What development phase is Lanreotide Autogel and Octreotide LAR in?
Lanreotide Autogel and Octreotide LAR is FDA-approved (marketed).
Related
- Manufacturer: Odense University Hospital — full pipeline